Lexicon Pharmaceuticals granted Novo Nordisk exclusive rights to develop LX9851, an oral obesity drug, with potential ...

Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and near-term milestone paymentsTHE WOODLANDS, Texas, ...

Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bw8705 ...

Skye‘s prime accomplishment in 2024 was the initiation and rapid advancement of its comprehensive Phase 2a clinical study of nimacimab, a ...

Enrollment completed in Phase 2a CBeyond™ trial of CB1 inhibitor, nimacimab, in obesity and overweightFaster-than-expected ...

Enrollment completed in Phase 2a CBeyond trial of CB1 inhibitor, nimacimab, in obesity and overweightFaster-than-expected enrollment enables full top-line Phase 2a data in late Q3/early Q4 2025, ahead ...

This is the BTK inhibitor of ours that's on the market ... pretty consistent over time that this is a single acting oral incretin, and the profile that we observed in the Phase 2 looks very ...

GLP-1-based therapy: incretin mimetics (GLP-1 analogues) and incretin enhancers (DPP-4 inhibitors) are now available for the treatment of Type 2 diabetes. Initial combination therapy with a DPP-4 ...